Navigation Links
AccessClosure Signs Distribution Agreement to Enter Into UK, Switzerland and France
Date:5/17/2011

MOUNTAIN VIEW, Calif., May 17, 2011 /PRNewswire/ -- AccessClosure, Inc., the market segment leader in extravascular closure devices, announced today an exclusive agreement with Biosensors International  for the distribution of the Mynx™ Vascular Closure Device throughout the United Kingdom, Switzerland and France. The extravascular Mynx device, designed for patient comfort while providing hemostasis without sutures or implants, will be sold as part of Biosensors' interventional cardiology product range.

"These European countries represent a meaningful market opportunity for us, and we are pleased to be able to partner with Biosensors' established sales force for the distribution of Mynx," said Gregory D. Casciaro, President and CEO of AccessClosure. "Distribution in international markets is a key component of AccessClosure's growth strategy, and provides an excellent complement to our direct sales presence in the United States."

Biosensors will join AccessClosure's existing and growing global network of distributors.  Biosensors is now the fifth largest drug-eluting stent (DES) supplier globally, marketing  its BioMatrix™ family of DES systems which offer the unique combination of Biolimus A9™, an anti-restenotic drug developed by Biosensors exclusively for use with DES, and an abluminally-coated biodegradable polymer. Biosensors has a well established direct presence in the UK, Switzerland and France, and will provide AccessClosure with broad and rapid access to those markets.

"We are pleased to offer the Mynx device as part of our interventional cardiology product range" said Jeffrey B. Jump, CEO of Biosensors. "The Mynx device, paired with our portfolio of drug-eluting and bare-metal stents, allows us to offer a more complete solution to our customers. The Mynx has had great success in the United States and other international markets, and we anticipate similar success in these European countries."

The Mynx Vascular Closure Device utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to immediately seal the femoral artery. Dissolving within 30 days, Mynx leaves nothing behind but a healed artery. The extravascular device is designed for increased patient comfort and clinical versatility. The Mynx, which received its first FDA approval in May 2007, has been used in over 800,000 procedures to date.

About AccessClosure, Inc.

Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendly vascular closure experience. For more information, please visit our website at http://www.accessclosure.com/

About Biosensors International

Biosensors International develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. With the increasing use of the BioMatrix™ family of drug-eluting stent systems, we are rapidly emerging as a leader in the global coronary stent market. For more information, please visit www.biosensors.com .


'/>"/>
SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
2. AccessClosure Announces Distribution Agreement for Radial Compression Band
3. Governor Daniels Signs Into Law Electronic Tracking Bill
4. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
5. Major Medical Diagnostics Manufacturer Signs Agreement to Use AmbiCom Wireless Solution in Its Urinalysis Product Line
6. Digital Assent Signs 100th PatientPad® Customer
7. Sysmex America Signs Distributorship Agreement With LABSCO
8. MedicaMetrix Signs Letter of Intent to Use Vytex® Natural Rubber Latex as Material of Choice in ProstaGlove™
9. Medical Care Technologies Inc. Signs Letter of Intent for Joint Venture in China
10. InstaCare Subsidiary Signs New Agreement for Expanded Management and Sales of Shasta Genstrip Into the $20 Billion Worldwide Diabetes Testing Market
11. More Dangerous Than Drunk Driving, Hope Paige Designs Promotes a THUMBAND for Safe Texting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 The ... to reach a value of USD 4.5 billion by ... Research, Inc. Proper closure of injured tissues post operation ... function. Postoperative leakages occur in 3% to 15% of ... are responsible for one third of postoperative deaths in ...
(Date:3/28/2017)... England , March 28, 2017 ... collaborative research with Cambridge ... Therapeutics Consortium   The Milner Therapeutics Institute today ... Consortium. Elysium Health has committed significant investment for collaborative projects ... the next four years. This is the first major research ...
(Date:3/27/2017)... March 27, 2017 Summary ... understand Eli Lilly and its partnering interests and activities since ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ... data. The report will be delivered in PDF ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... In its ongoing effort to educate consumers ... and published an informational resource that addresses frequently asked questions. , “ ... site’s team of third party administrator (TPA) contributors regularly receives as employers, benefit ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin ... one of few medical professionals in the country to sit on the 2017 National ... Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a small ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... offered by the American Association of Integrative Medicine and available for application on ... at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work ... a variety of business channels. , While many results are clear, much of PR ... program. , When it comes to measurement, firms should always take an all-inclusive ...
(Date:3/28/2017)... ... ... With expansion and efficiency in mind, Patten Seed Company completed relocation of its ... in Marshallville in 2006, and a bagging and shipping facility has been in place ... Seed operations to the Middle Georgia location from their previous home in Lakeland, Georgia. ...
Breaking Medicine News(10 mins):